BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.

Because patients with essential thrombocythemia (ET) or polycythemia vera (PV) — rare types of blood cancers known as myeloproliferative neoplasms (MPNs) — experience a range of symptoms that can significantly impact their quality of life, it’s important that patients communicate what they’re experiencing with their health care team.

June 2, 2022

- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –

- Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation -

BOSTON, May 25, 2022  – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated

PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”

Key Points
Structural racism (SR) assessed by census tract variables accounts for nearly all Black-white and Hispanic-white disparity in AML survival.

Structural Racism is a stronger mediator of survival disparities than molecular features, co-morbidities, healthcare access and treatment.

Abstract
Background
Despite widespread use, little is known about how adolescents and young adults (AYA) with cancer use social media (SM). This research characterized use and self-reported SM experiences among AYA with cancer.

Procedure
AYA, aged 12-26 years, receiving cancer care completed a mixed-methods survey regarding SM experiences. Clinical information was obtained from the electronic medical record. Data were analyzed with descriptive statistics, t tests, and qualitative content analysis.

Editor's note:  Here's an update on Mychaela (see Stories of Hope)

Mychaela Lovelace is a sophomore at Michigan State University majoring in kinesiology in the College of Education, and is a scholar and mentor in the Dow STEM Scholars Program.

Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.

Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15. His father, Benjamin, developed kidney cancer when Stone was just 5 years old, and 10 years later, the disease metastasized and took the man’s life.

Stone says he went from being middle class to poor rapidly after his father died. “And that sort of gave me the incentive to work hard,” he said.